San Diego’s Ambrx Names New CEO, CSO

Xconomy San Diego — 

San Diego-based Ambrx, Inc., a clinical stage biotechnology company developing optimized protein therapeutics known as bio-conjugates, named Dr. Tiecheng (Alex) Qiao as CEO. He was previously a partner at Coentre, a private angel investment firm. Ambrx also named Dr. Feng Tian, formerly vice president of science and technology, China, chief science officer, a newly-created position.